Achaogen Company Profile (NASDAQ:AKAO)

About Achaogen (NASDAQ:AKAO)

Achaogen logoAchaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AKAO
  • CUSIP: N/A
  • Web:
  • Market Cap: $775.86 million
  • Outstanding Shares: 35,853,000
Average Prices:
  • 50 Day Moving Avg: $23.28
  • 200 Day Moving Avg: $18.04
  • 52 Week Range: $3.12 - $27.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.45
  • P/E Growth: -0.13
Sales & Book Value:
  • Annual Revenue: $43.39 million
  • Price / Sales: 17.88
  • Book Value: $2.19 per share
  • Price / Book: 9.88
  • EBIDTA: ($54,980,000.00)
  • Net Margins: -147.80%
  • Return on Equity: -143.44%
  • Return on Assets: -71.22%
  • Debt-to-Equity Ratio: 0.77%
  • Current Ratio: 4.00%
  • Quick Ratio: 4.00%
  • Average Volume: 886,256 shs.
  • Beta: 1.35
  • Short Ratio: 3.96

Frequently Asked Questions for Achaogen (NASDAQ:AKAO)

What is Achaogen's stock symbol?

Achaogen trades on the NASDAQ under the ticker symbol "AKAO."

How were Achaogen's earnings last quarter?

Achaogen Inc (NASDAQ:AKAO) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.39. The business earned $7.46 million during the quarter, compared to analysts' expectations of $3.81 million. Achaogen had a negative net margin of 147.80% and a negative return on equity of 143.44%. The firm's quarterly revenue was up 27.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.66) EPS. View Achaogen's Earnings History.

Where is Achaogen's stock going? Where will Achaogen's stock price be in 2017?

8 analysts have issued 12 month target prices for Achaogen's stock. Their predictions range from $10.00 to $31.00. On average, they expect Achaogen's stock price to reach $25.43 in the next year. View Analyst Ratings for Achaogen.

What are analysts saying about Achaogen stock?

Here are some recent quotes from research analysts about Achaogen stock:

  • 1. Cowen and Company analysts commented, "We are assuming coverage of AKAO with an Outperform." (5/5/2017)
  • 2. Needham & Company LLC analysts commented, "Achaogen mgmt provided a 4Q16 corporate update yesterday. Company remains on track for plazomicin NDA submission 2H17. Details around manufacturing/ CMC were provided, including role for Pfizer McPherson facility in fill/ finish. An FDA Warning Letter was issued to Pfizer last month for matters unrelated to plazomicin at facility. We assume resolution is likely before PDUFA date in 2018. We await additional information on new oral beta-lactam/ BLI cUTI program (C-Scape), but believe commercial opportunity for oral drug in this indication is one of most attractive areas in antibiotic space." (3/15/2017)
  • 3. Aegis analysts commented, "Yesterday after market close, Achaogen announced fourth quarter results, reporting revenue of $10.7 mil vs. street consensus estimates of $12.4 mil and GAAP-EPS of $(1.04) vs. consensus of $(0.49). The EPS miss comes primarily from a $16.9 mil expense recorded in the fourth quarter related to changes in warrants and derivative liabilities that was associated with the capital raise completed in June, 2016. Achaogen is a clinical stage development company, as such we believe the financials are less important, milestones and catalysts tend to drive valuation for these types of companies." (3/15/2017)
  • 4. According to Zacks Investment Research, "Achaogen, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae. Achaogen, Inc. is headquartered in South San Francisco, California. " (3/8/2017)
  • 5. Wedbush analysts commented, "With a favorable risk/benefit profile demonstrated in each both CARE and EPIC patient populations, we expect plazomicin will become the treatment of choice for CRE infections. We also believe AKAO represents an attractive takeout candidate, although this may depend on additional clarity on the market opportunity and plazomicin's label potential. We are increasing our PT to $23 based on raising our pricing expectations upwards." (1/31/2017)

Who are some of Achaogen's key competitors?

Who are Achaogen's key executives?

Achaogen's management team includes the folowing people:

  • Bryan E. Roberts Ph.D., Chairman of the Board
  • Kenneth J. Hillan, President, Chief Executive Officer, Director
  • Blake Wise, President, Chief Operating Officer
  • Tobin Schilke, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  • Lee Swem, Senior Vice President, Chief Scientific Officer
  • Zeryn Sarpangal, Senior Vice President - Corporate and People Strategy
  • Janet Dorling, Chief Commercial Officer
  • Alan B. Colowick M.D., Director
  • John C. Doyle, Director
  • Halley E. Gilbert Esq., Director

Who owns Achaogen stock?

Achaogen's stock is owned by many different of retail and institutional investors. Top institutional investors include NEA Management Company LLC (0.00%), FMR LLC (0.00%), Versant Venture Management LLC (3.58%), Foresite Capital Management III LLC (0.00%), Vanguard Group Inc. (0.00%) and Point72 Asset Management L.P. (1.60%). Company insiders that own Achaogen stock include Blake Wise, Equity Opportunities Iv Growth, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Institutional Ownership Trends for Achaogen.

Who sold Achaogen stock? Who is selling Achaogen stock?

Achaogen's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Sphera Funds Management LTD., EAM Investors LLC, Point72 Asset Management L.P., Russell Investments Group Ltd., Essex Investment Management Co. LLC, Tudor Investment Corp ET AL and Candriam Luxembourg S.C.A.. Company insiders that have sold Achaogen stock in the last year include Blake Wise, Gary Loeb, Ian Friedland, Kenneth J Hillan, Tobin Schilke and Zeryn Sarpangal. View Insider Buying and Selling for Achaogen.

Who bought Achaogen stock? Who is buying Achaogen stock?

Achaogen's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, TimesSquare Capital Management LLC, Goldman Sachs Group Inc., Spark Investment Management LLC, Bank of America Corp DE, Vanguard Group Inc., Laurion Capital Management LP and Nicholas Investment Partners LP. View Insider Buying and Selling for Achaogen.

How do I buy Achaogen stock?

Shares of Achaogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achaogen's stock price today?

One share of Achaogen stock can currently be purchased for approximately $21.64.

MarketBeat Community Rating for Achaogen (NASDAQ AKAO)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Achaogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Achaogen (NASDAQ:AKAO) (?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $25.43 (17.51% upside)

Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
5/9/2017Stifel NicolausReiterated RatingBuy -> Buy$28.00 -> $31.00LowView Rating Details
4/24/2017WedbushReiterated RatingOutperform$28.00HighView Rating Details
3/30/2017AegisDowngradeBuy -> Hold$29.00LowView Rating Details
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00MediumView Rating Details
1/24/2017GuggenheimReiterated RatingBuy$30.00N/AView Rating Details
1/4/2017Leerink SwannInitiated CoverageOutperform$21.00N/AView Rating Details
9/26/2016SunTrust Banks, Inc.Reiterated RatingBuy$10.00N/AView Rating Details
8/10/2015Cantor FitzgeraldReiterated RatingBuy$13.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Achaogen (NASDAQ:AKAO)
Earnings by Quarter for Achaogen (NASDAQ:AKAO)
Earnings History by Quarter for Achaogen (NASDAQ:AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.54)($0.93)$3.81 million$7.46 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.49)($1.04)$13.33 million$10.73 millionViewN/AView Earnings Details
11/7/2016Q3($0.61)($0.41)$8.72 million$16.05 millionViewListenView Earnings Details
8/8/2016Q2($0.67)($0.87)$5.58 million$9.14 millionViewN/AView Earnings Details
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.46)($0.48)$5.10 million$4.48 millionViewN/AView Earnings Details
8/10/2015Q2 2015($0.20)($0.05)$8.65 million$12.04 millionViewN/AView Earnings Details
5/11/2015Q1 2015($0.25)($0.34)$5.00 million$4.88 millionViewN/AView Earnings Details
3/16/2015Q4 2014($0.33)($0.27)$4.96 million$4.26 millionViewN/AView Earnings Details
11/10/2014Q314($0.18)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.19)($0.20)$5.99 million$5.20 millionViewN/AView Earnings Details
5/12/2014Q114($0.21)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Achaogen (NASDAQ:AKAO)
2017 EPS Consensus Estimate: ($2.64)
2018 EPS Consensus Estimate: ($3.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.48)($0.54)
Q2 20174($0.71)($0.63)($0.68)
Q3 20174($0.88)($0.64)($0.73)
Q4 20174($0.86)($0.62)($0.70)
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.79)($0.79)($0.79)
Q3 20181($0.82)($0.82)($0.82)
Q4 20181($0.92)($0.92)($0.92)
(Data provided by Zacks Investment Research)


Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Achaogen (NASDAQ:AKAO)
Insider Ownership Percentage: 13.80%
Institutional Ownership Percentage: 44.47%
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Institutional Ownership by Quarter for Achaogen (NASDAQ:AKAO)
Insider Trades by Quarter for Achaogen (NASDAQ:AKAO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/26/2017Gary LoebGeneral CounselSell521$16.78$8,742.38View SEC Filing  
1/26/2017Ian FriedlandInsiderSell695$16.78$11,662.10View SEC Filing  
1/26/2017Kenneth J. HillanCEOSell1,431$16.78$24,012.18View SEC Filing  
1/26/2017Tobin SchilkeCFOSell955$16.78$16,024.90View SEC Filing  
1/26/2017Zeryn SarpangalVPSell781$16.78$13,105.18View SEC Filing  
12/19/2016Equity Opportunities Iv GrowthMajor ShareholderBuy500,000$13.50$6,750,000.00View SEC Filing  
9/27/2016Blake WiseCOOSell3,632$4.30$15,617.60View SEC Filing  
9/27/2016Zeryn SarpangalVPSell1,069$4.30$4,596.70View SEC Filing  
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Achaogen (NASDAQ:AKAO)
Latest Headlines for Achaogen (NASDAQ:AKAO)
DateHeadline logoAchaogen, Inc. breached its 50 day moving average in a Bearish Manner : AKAO-US : May 26, 2017 - May 26 at 3:40 PM logoAchaogen (AKAO) Prices 5M Share Offering at $22.50/Sh - - May 26 at 1:53 AM logoAchaogen's Plazomicin Gets Breakthrough Therapy Designation - Nasdaq - May 24 at 3:24 PM logoAchaogen (AKAO) Commences 5M Share Offering of Common Stock - - May 24 at 7:07 AM logo4 Stocks Moving On Both News & Technicals - May 19 at 9:38 AM logoTop 4 Pharmaceutical Stocks for 2017 - May 19 at 9:38 AM logoAchaogen Inc (AKAO) Expected to Earn FY2017 Earnings of ($2.70) Per Share - May 11 at 11:42 AM logoQ2 2017 EPS Estimates for Achaogen Inc Cut by SunTrust Banks (AKAO) - May 11 at 9:26 AM logoAchaogen Inc Forecasted to Post Q2 2017 Earnings of ($0.71) Per Share (AKAO) - May 11 at 9:26 AM logoQ2 2017 Earnings Forecast for Achaogen Inc Issued By Wedbush (AKAO) - May 11 at 9:24 AM logoQ2 2017 EPS Estimates for Achaogen Inc (AKAO) Lowered by Analyst - May 11 at 9:24 AM logoFY2020 EPS Estimates for Achaogen Inc Decreased by Analyst (AKAO) - May 10 at 3:38 PM logoEquities Analysts Issue Forecasts for Achaogen Inc's FY2019 Earnings (AKAO) - May 10 at 3:20 PM logoQ1 2018 Earnings Estimate for Achaogen Inc Issued By Wedbush (AKAO) - May 10 at 1:08 PM logoAchaogen Inc (AKAO) Announces Earnings Results, Misses Estimates By $0.39 EPS - May 9 at 10:22 AM logoAchaogen's (AKAO) "Buy" Rating Reiterated at Stifel Nicolaus - May 9 at 9:15 AM logoAchaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update - May 8 at 8:24 PM logoAchaogen reports 1Q loss - May 8 at 5:17 PM logoInvestor Network: Achaogen, Inc. to Host Earnings Call - May 8 at 11:14 AM logoCowen and Company Reaffirms Outperform Rating for Achaogen Inc (AKAO) - May 5 at 3:44 PM logoAchaogen (AKAO) Receives $10.5M Grant, $10M Equity Investment from Bill & Melinda Gates Foundation to Develop ... - - May 5 at 3:26 PM logoAchaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria - May 5 at 3:26 PM logoAchaogen Inc (AKAO) Expected to Announce Earnings of -$0.50 Per Share - May 5 at 11:18 AM logoAchaogen (AKAO) Receiving Somewhat Positive Press Coverage, Study Shows - May 4 at 3:52 PM logoAchaogen Inc (AKAO) Receives Average Rating of "Buy" from Brokerages - May 3 at 8:40 AM logoAchaogen (AKAO) Receiving Somewhat Negative Media Coverage, Report Shows - May 1 at 11:45 AM logoAchaogen to Host Conference Call and Webcast of First Quarter 2017 Financial Results on May 8, 2017 - May 1 at 9:43 AM logoAchaogen Inc (AKAO) Set to Announce Earnings on Wednesday - May 1 at 9:32 AM logoAchaogen, Inc. – Value Analysis (NASDAQ:AKAO) : April 28, 2017 - April 28 at 9:22 PM logoPositive News Coverage Extremely Likely to Affect Achaogen (AKAO) Share Price - April 28 at 9:46 AM logoPositive News Coverage Very Likely to Affect Achaogen (AKAO) Share Price - April 25 at 2:30 PM logoAchaogen Inc (AKAO) Stock Rating Reaffirmed by Wedbush - April 24 at 10:14 PM logoPositive News Coverage Extremely Likely to Impact Achaogen (AKAO) Share Price - April 21 at 9:07 AM logoHartwell J M Limited Partnership Buys Apple, UnitedHealth Group, Mesabi Trust, Sells Anadarko ... - April 19 at 3:26 PM logoAchaogen (AKAO) Earning Somewhat Critical News Coverage, Report Shows - April 18 at 8:50 AM logoTechnical Reports on Biotech Stocks -- CytRx, Achaogen, Jaguar Animal, and Illumina - PR Newswire (press release) - April 18 at 7:04 AM logo$3.5 Million in Sales Expected for Achaogen Inc (AKAO) This Quarter - April 16 at 9:00 AM logoZacks: Analysts Expect Achaogen Inc (AKAO) Will Announce Earnings of -$0.50 Per Share - April 14 at 11:30 AM logoSomewhat Negative News Coverage Somewhat Likely to Impact Achaogen (AKAO) Share Price - April 13 at 10:47 AM logoAchaogen Inc (AKAO) Given Consensus Recommendation of "Buy" by Analysts - April 7 at 9:05 PM logoAchaogen Inc (AKAO) Downgraded by Aegis to Hold - April 5 at 9:16 AM logoAchaogen Inc (AKAO) Sees Large Increase in Short Interest - April 4 at 2:35 PM logoAchaogen to Present at Needham & Company’s 16th Annual Healthcare Conference - March 30 at 3:50 PM logoAchaogen Inc (AKAO) Downgraded to "Hold" at Aegis - March 30 at 11:49 AM logoWedbush Reiterates "Outperform" Rating for Achaogen Inc (AKAO) - March 21 at 8:28 AM logoAchaogen Inc to Post Q1 2017 Earnings of ($0.56) Per Share, Wedbush Forecasts (AKAO) - March 20 at 9:55 AM logoAchaogen Inc (AKAO) PT Raised to $28.00 at Stifel Nicolaus - March 15 at 2:57 PM logoAchaogen Inc (AKAO) Posts Quarterly Earnings Results, Misses Expectations By $0.55 EPS - March 14 at 9:27 PM logoAchaogen Inc. (AKAO) Is Dropping After Wider Than Expected Q4 Loss - March 14 at 8:24 PM logoAchaogen Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update - March 14 at 8:24 PM



Achaogen (AKAO) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff